31 October 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a revenue interest financing agreement with Sagard Healthcare Partners for a total of $32.5 million upfront in return for payments based on U.S. net sales of ganaxolone, including the recently approved ZTALMY® (ganaxolone) oral suspension CV.
04 October 2022
In a first of its kind partnership, the Alabama Department of Public Health (ADPH) and binx health, a healthcare technology and diagnostics company, enables access to routine remote sample collection for sexually transmitted infections (STIs) and subsequent treatment for Alabama residents.
29 September 2022
Recently, Cothera Bioscience, the parent company of Percans Oncology, has made new progress in the Phase II clinical trial of MYC gene inhibitor PC-002 in China. Beijing Cancer Hospital is conducting a multicenter, open-label, exploratory dose-ranging phase II study of Sepantronium Bromide in patients with relapsed/refractory c-Myc rearranged high-grade B-cell lymphoma (HGBCL) (clinical trial approval number: 2022LP00392).
22 September 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, exercised its first contract option, valued at approximately $12.3 million, to support U.S. onshoring of the manufacturing capabilities for ganaxolone active pharmaceutical ingredient (API).
Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million
30 August 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has closed on the sale of its Rare Pediatric Disease Priority Review Voucher for $110 million. The $110 million of gross funds have been received and are in addition to the $92.3 million in cash and cash equivalents reported as of June 30, 2022.
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
11 August 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the second quarter ended June 30, 2022.
28 July 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the U.S. commercial launch of ZTALMY® (ganaxolone) oral suspension, CV for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older.
Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million
14 July 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $110 million.
Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million
14 July 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $110 million.
09 June 2022
Ernst & Young LLP (EY US) today announced that Jeffrey Luber, Chief Executive Officer of binx health, was named an Entrepreneur Of The Year® 2022 New England Award winner. Entrepreneur Of The Year® is one of the preeminent competitive business awards for entrepreneurs and leaders of high-growth companies who think big to succeed. An independent panel of judges selected Jeffrey Luber based on his entrepreneurial spirit, purpose, growth, and impact, among other core contributions and attributes.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia has expanded the mandatory health insurance program for 2024-2026
29 March 2024
Russian scientists have developed new TB vaccines for both injection and nasal administration.
29 March 2024
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024